Impact of cardiovascular risk screening in an academic institution, Benghazi, Libya

Abstract :

Cardiovascular disease (CVD) is a leading cause of mortality in Libya, driven by obesity, hypertension, diabetes, and smoking. Inadequate screening contributes to the widespread undiagnosed status of risk factors, with university staff particularly vulnerable due to occupational and lifestyle factors. This study aimed to assess the prevalence of cardiovascular risk factors, evaluate risk awareness, and determine the impact of a pharmacist-led screening intervention on behavioral intentions among employees in an academic institution in Benghazi, Libya. A cross-sectional interventional study was conducted among 179 university employees. Data were collected in two phases. In the baseline phase, participants completed questionnaires on demographics, lifestyle, medical history, and CVD awareness, followed by clinical measurements. After pharmacist-led counseling and personalized feedback, post-intervention assessments of awareness and behavioral intentions were performed. Participants were mostly female (62.6%), aged 20-35 years (61.5%), and Libyan (89.9%). The most prevalent undiagnosed CVD risk factors were dyslipidemia (66.5%), overweight (63.1%), and hypertension (20.7%). Post-screening awareness was high (mean score 9.06/10), especially for obesity (99.4%) and hypertension (97.2%). The pharmacist-led intervention strongly improved lifestyle intentions: increasing physical activity (97.8%), improving diet (98.9%), attending regular check-ups (92.2%), and using digital monitoring (91.6%). Significant associations were found between socio-demographic factors and CVD risks, as well as between lifestyle habits and clinical outcomes. A high prevalence of undiagnosed CVD risk factors exists among university employees despite good awareness levels. Pharmacist-led workplace screening effectively increased intentions to adopt healthier behaviors, supporting the integration of clinical pharmacists into wellness programs to reduce the CVD burden in Libya.


References

1. World Health Organization. Cardiovascular diseases (CVDs). WHO; 2023. Accessed July 20th, 2026. https:// www. who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. Soleimani H, Nasrollahizadeh A, Nasrollahizadeh A, Razeghian I, Molaei MM, Hakim D, et al. Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the Global Burden of Disease Study 1990-2021. BMC Cardiovascular Disorders. 2024; 24(1): 712. doi: 10.1186/s12872-024-04390-0
3. Altajori AA, Elshrek YM. Prevalence of hypertension and its associated risk factors among patients with type 2 diabetes mellitus in Benghazi, Libya. Ibnosina Journal of Medicine and Biomedical Sciences. 2017; 9(4): 123-129. doi: 10.9734/AJMAH/2017/35830
4. Elmiladi SA, Elgdhafi EO. Prevalence of cardiovascular risk factors in Libyan patients with type 2 diabetes mellitus, 2013-2022. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2023; 3(2): 27-33. doi: 10.5281/ zenodo.7877416
5. Bheleel O, Abdulhamid A, Elmuaget H, Grash H, Abdelhamid MHM, Alhadi I. Assessment of risk factors associated with coronary artery disease (CAD) in Western Libyan Patients. Cardiovascular Therapeutics. 2025; 2025: 1396974. doi: 10.1155/cdr/1396974
6. Wikipedia contributors. Health in Libya. Wikipedia. Updated 2025. Accessed July 20th, 2026. https://en.Wikipedia. org/wiki/Health_in_Libya
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004; 364(9438): 937-952. doi: 10.1016/S0140-6736(04)17018-9
8. Le Goff D, Perraud G, Aujoulat P, Deriennic J, Guillou M. Screening for cardiovascular risk in the general population: The SPICES implementation survey. Frontiers in Medicine (Lausanne). 2023; 9: 1058090. doi: 10.3389 /fmed.2022.1058090
9. Sousa TF, Nahas MV, Silva DAS, Duca GFD. Factors associated with obesity in Brazilian university employees. Revolution Nutrition. 2013; 26(5): 539-549. doi: 10.1590/S1415-52732013000500007
10. Silva DAS, Petroski EL, Peres MA, Lopes AS. Prevalence and factors associated with cardiovascular risk factors in university employees. Revista de Saude Publica. 2016; 50: 66. doi: 10.1590/S1518-8787.2016050006303
11. Zammit N, Belgacem WB, Ghammam R, Fredj SB, Krifa R, Ouertani M, et al. Screening and health education practices related to cardiovascular risk factors among adults: Results of a household’s survey in Sousse, Tunisia. Scientific Reports. 2022; 12(1): 9334. doi: 10.1038/s41598-022-23600-3
12. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nature Reviews Cardiology. 2015; 12(9): 508-530. doi: 10.1038/nrcardio. 2015.82
13. Elfil M, Negida A. Sampling methods in clinical research: an educational review. Emergency (Tehran). 2017; 5(1): e52. doi: 10.22037/emergency. v5i1.15215
14. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing Clinical Research. 4th ed. Lippincott Williams and Wilkins; 2013. doi: 10.1007/978-1-4757-4242-8
15. Woringer M, Nielsen JJ, Zibarras L, Evason J, Kassianos AP, Harris M, et al. Development of a questionnaire to evaluate patients’ awareness of cardiovascular disease risk in England’s National Health Service Health Check preventive cardiovascular programme. British Medical Journal Open. 2017; 7(9): e014413. doi: 10.1136/bmjopen-2016-014413
16. Taiek N, El Fadili NEH, Belkacem A, Cheikh AA, Kabbadj K, Damoun N, et al. The knowledge assessment of cardiovascular disease risk factors: a cross-sectional study. Cureus. 2024; 16(5): e59774. doi: 10.7759/cureus.59774
17. World Health Organization (2023) 2023 STEPS Data Book Libya. World Health Organization. Available at: https://www.who.int/publications/m/item/2023-steps-databook-libya
18. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. The Journal of the American College of Cardiology. 2019; 74(20): 2529-2532. doi: 10.1016/j.jacc.2019.10.009
19. Manla Y, Almahmeed W. The pandemic of coronary heart disease in the Middle East and North Africa: What clinicians need to know. Current Atherosclerosis Reports. 2023; 25(9): 543-557. doi: 10.1007/s11883-023-01126-x
20. Jamiu MO, Maiha BB, Danjuma NM, Giwa A. Educational intervention on knowledge of hypertension and lifestyle/dietary modification among hypertensive patients attending a tertiary health facility in Nigeria. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2024; 4(1): 1-11. doi: 10.5281/zenodo.10535778
21. Ghamri RA. Knowledge of cardiovascular diseases and associated risk factors in the general adult population of Jeddah, Saudi Arabia: A cross-sectional study examining gender disparities. Medicine (Baltimore). 2024; 103(24): e38566. doi: 10.1097/MD.0000000000038566
22. Bakhsh HT. Impact of pharmacist interventions on health outcomes of patients with type 2 diabetes mellitus in the Middle East: A systematic review. Integrated Pharmacy Research and Practice. 2025; 14: 85-98. doi: 10.2147/IPRP. S515197
23. Taghizadeh P. The role of pharmacists in managing conditions like hypertension: The case of Northern Cyprus. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2025; 5(3): 28-37. doi: 10.5281/zenodo. 15921080

Citation :

Elferjany SM, et al. Impact of cardiovascular risk screening in an academic institution, Benghazi, Libya. Mediterr J Pharm Pharm Sci. 2026; 6(3): 40-49. [Article number: 260]. https://doi.org/10.5281/zenodo.0000000